Comparative Pharmacology
Head-to-head clinical analysis: METOCURINE IODIDE versus VECURONIUM BROMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METOCURINE IODIDE versus VECURONIUM BROMIDE.
METOCURINE IODIDE vs VECURONIUM BROMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive nicotinic acetylcholine receptor antagonist at the neuromuscular junction, blocking acetylcholine binding and preventing muscle contraction.
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine binding and muscle contraction.
Initial dose 0.2 mg/kg IV; maintenance doses of 0.1-0.15 mg/kg IV as needed for neuromuscular blockade.
IV bolus: 0.08-0.1 mg/kg for intubation; maintenance: 0.01-0.015 mg/kg every 12-15 minutes as needed or continuous infusion 0.05-0.1 mg/kg/hour.
None Documented
None Documented
Terminal elimination half-life: 3-5 hours in patients with normal renal function. Prolonged in renal impairment.
Terminal elimination half-life: 1.2-1.9 hours (65-115 minutes). Clinically, recovery from neuromuscular blockade is faster than with pancuronium; prolonged in renal and hepatic impairment.
Renal: 85-90% unchanged; biliary/fecal: <5%.
Primarily renal (40-60% unchanged in urine within 24 hours); biliary/fecal elimination accounts for <20%. Approximately 10-20% as 3-desacetylvecuronium (active metabolite) in urine.
Category C
Category C
Neuromuscular Blocker
Neuromuscular Blocker